Pasithea's Strategic Gambit: Refining a Trial to Redefine NF1 Treatment

MIAMI, June 16, 2026 – Pasithea Therapeutics announced today it is amending the clinical study protocol for its Phase 1/1b trial of PAS-004, a drug candidate for Neurofibromatosis Type 1 (NF1). On the surface, it's a procedural update. Dig deeper, and it’s a calculated strategic maneuver that reveals a company playing the long game, aiming not just to compete, but to redefine the standard of care for a devastating rare disease.

The amendments are significant. The Miami-based biotech is adding two higher dose levels (24mg and 32mg), evaluating intermediate doses, and extending the potential treatment period for early-phase patients from a few months to up to 18 months. This isn't just a minor course correction; it's a fundamental enhancement of the trial's architecture, designed to extract a richer, more robust dataset far earlier than a conventional trial design would allow. While the company remains on track for an interim data update in the fourth quarter of this year, the changes signal a profound confidence in its lead asset and a sophisticated approach to navigating the complex world of orphan drug development.

A Calculated Move to De-Risk and Accelerate

The decision to expand the dose-escalation phase (Part A) of the NF1 study is a textbook example of modern adaptive trial design, a strategy increasingly vital in rare disease research where patient populations are small and every data point is precious. By testing a wider range of doses and allowing for longer treatment durations at this early stage, Pasithea is front-loading its data collection efforts. This approach aims to build a comprehensive understanding of PAS-004’s safety, tolerability, and preliminary efficacy profile before committing to a larger, more expensive expansion cohort (Part B) and subsequent pivotal studies.

"We believe increasing the breadth and depth of Part A of the NF1 study will help inform dose selection for Part B and our future registrational studies," stated Dr. Kartik Krishnan, Pasithea’s Chief Medical Officer. "I am pleased that we rapidly enrolled and dosed an additional 6 patients and that the amendments will allow us to provide more comprehensive data in 2026."

This strategy has two core benefits. First, it de-risks the entire development program. By identifying the optimal dose—one that balances maximum efficacy with minimal side effects—early on, the company significantly increases the probability of success in later, more costly phases. Second, it has the potential to accelerate the overall timeline. The inclusion of an 18-month treatment period in Part A is particularly telling. It allows Pasithea to gather long-term safety and durability data, crucial components for any regulatory submission, concurrently with its dose-finding efforts. This parallel processing could shave months, or even years, off the traditional, sequential development path.

This proactive approach is further bolstered by the Fast Track Designation the FDA granted to PAS-004 in April. The designation, reserved for drugs addressing serious conditions with unmet medical needs, facilitates more frequent communication with the agency. The robust data package generated from this amended protocol will provide a solid foundation for these critical regulatory discussions, potentially smoothing the path toward approval.

The Unmet Need in Neurofibromatosis Type 1

To understand the significance of Pasithea’s strategy, one must understand the disease it aims to treat. Neurofibromatosis Type 1 is a genetic disorder that causes tumors, known as neurofibromas, to grow on nerve tissue throughout the body. While some cases are mild, many patients develop plexiform neurofibromas (PNs)—complex, sprawling tumors that grow along nerve branches. These PNs can cause severe pain, disfigurement, organ compression, and motor dysfunction. For the 30-50% of NF1 patients who harbor them, PNs represent a constant threat, with a risk of transforming into aggressive, malignant cancers.

For decades, the primary management for these tumors was "watchful waiting" or high-risk surgery that often resulted in incomplete removal and nerve damage. The landscape shifted with the approval of the first MEK inhibitor, selumetinib (Koselugo), which offered the first effective systemic therapy. MEK inhibitors work by blocking a key protein in the MAPK signaling pathway, which is hyperactive in NF1 and drives tumor growth.

However, existing therapies are not a panacea. While they represent a monumental step forward, response rates are modest, and the treatments come with a significant burden of side effects, including rash, gastrointestinal issues, and fatigue. This leaves a clear and urgent unmet need for next-generation therapies that can offer improved efficacy, a better safety profile, or both. For patients and their families, the prospect of a new agent that could shrink tumors more effectively or be tolerated for longer periods represents a profound source of hope.

Navigating a Competitive MEK Inhibitor Landscape

Pasithea is entering a field with established players, most notably AstraZeneca/Merck with Koselugo and SpringWorks Therapeutics with its own MEK inhibitor, mirdametinib. To succeed, PAS-004 cannot simply be another "me-too" drug; it must offer a distinct advantage. The company believes that advantage lies in its molecular architecture.

PAS-004 is a "next-generation macrocyclic MEK inhibitor." The term "macrocyclic" refers to the drug's rigid, ring-like chemical structure. This design is intended to confer greater selectivity for the MEK target and optimize its pharmacokinetic properties—how the drug is absorbed, distributed, and eliminated by the body. In theory, this could translate into a more sustained suppression of the MAPK pathway at a lower dose, potentially leading to fewer off-target side effects that are often linked to high peak concentrations of a drug in the bloodstream. If this hypothesis holds true in the clinic, PAS-004 could offer a superior therapeutic window, delivering more powerful anti-tumor activity with improved tolerability.

The amended trial protocol, with its enhanced MRI scans and detailed measurements of both plexiform and cutaneous neurofibromas, is designed to prove precisely this point. By capturing granular data on tumor response across a wider dose range, Pasithea is building the evidence base to demonstrate differentiation from its competitors.

The Corporate Backdrop: Funding and Focus

An ambitious clinical strategy requires a solid financial foundation. The expansion of a clinical trial inevitably increases costs related to patient care, drug manufacturing, and data analysis. Pasithea appears prepared for this. A $60 million public offering completed in December 2025 provided the company with a cash runway projected to last into the first half of 2028, giving it the financial stability to execute this enhanced clinical plan without immediate funding pressures.

The company has also strengthened its leadership, appointing Dr. Kartik Krishnan, a veteran with over two decades of clinical development experience, as its Chief Medical Officer in May. This move signals a commitment to rigorous clinical execution as the PAS-004 program advances. While the company's stock has faced pressure, receiving a non-compliance notice from Nasdaq earlier this year regarding its minimum bid price, its operational focus remains squarely on its clinical pipeline. For a clinical-stage biotech, progress is measured not by daily stock fluctuations, but by trial milestones. The upcoming interim data in late 2026 will be the next critical test, offering the first glimpse into whether Pasithea's strategic gambit on PAS-004 will pay off.